Abstract
Introduction
The enVista Aspire (EA) and enVista Aspire Toric (ETA) lenses are monofocal intraocular lenses (IOLs) with intermediate-optimized optics designed to broaden depth of focus. This study describes outcomes with these IOLs in real-world clinical practice.Methods
This multicenter, retrospective, real-world case series study included six cataract surgeons in the USA. Surgeons provided a convenience sample of ≥ 5 study IOL implantation cases and completed a retrospective experience survey. Outcomes included visual acuity (corrected and uncorrected distance visual acuity [CDVA, UDVA] and uncorrected intermediate visual acuity [UIVA]), refractive outcomes, and safety (adverse events and visual changes). The surgeon survey captured IOL utilization patterns and surgeon experience as supplementary descriptive findings.Results
The analysis included 141 eyes (88 EA and 53 ETA) from 84 patients. Patients were aged 62-84 years, with postoperative follow-up ranging from approximately Days 1-6 to 4 months. At the last available postoperative visit, monocular CDVA of 20/25 or better was achieved by 97.2% of EA and 94.9% of ETA eyes; monocular UDVA of 20/25 or better by 71.3% and 84.9%, respectively; and monocular UIVA of 20/32 or better by 76.6% and 93.0%, respectively. A binocular UIVA of 20/32 or better was achieved by 100% of patients. Mean ± SD SEQ outcome was -0.06 ± 0.30 D (EA) and 0.00 ± 0.32 D (ETA). No serious adverse events were documented in the available records. Findings from the surgeon survey indicated positive surgeon experience with the qualities and outcomes of the study IOLs.Conclusions
In this descriptive real-world analysis, a high proportion of eyes implanted with the study IOLs achieved good distance and functional intermediate vision.